In conclusion, the present study has revealed that a combination of sorafenib and CuB had synergistic antitumor effects on cellular proliferation and apoptosis in HCC cells, and also that inhibition of STAT3 phosphorylation was involved in the synergistic molecular mechanisms. The gene discussed is STAT3; the disease is hepatocellular carcinoma.